stockrow
Friday 6 November 2026
Export NYXH’s income statement to Excel — free account
Nyxoah SA
NYXH Healthcare Medical Devices
Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024.
- Revenue
- +486.6%
- EPS
- −6.35%
- Free cash flow
- +4.01%
- Total debt
- +185.4%
Quarter to June 2026, against a year earlier
0.85
0.04
+4.94%
Follow NYXH
Alert me
Nyxoah SA (NYXH) P/E ratio
Nyxoah SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LUCD Lucid Diagnostics Inc. compare | n/m |
| ECOR electroCore, Inc. compare | n/m |
| MBOT Microbot Medical Inc. compare | n/m |
| SERA Sera Prognostics, Inc. compare | n/m |
| CATX Perspective Therapeutics, Inc. compare | n/m |
| NYXH Nyxoah SA | n/m |
| OM Outset Medical, Inc. compare | n/m |
| HYPR Hyperfine, Inc. compare | n/m |
| ZOMDF Zomedica Corp. compare | n/m |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)